Xiaorong Dong

机构：Chinese Academy of Sciences, Wuhan Union Hospital, Union Hospital, Shanghai Institute of Ceramics, Union Hospital, University of Chinese Academy of Sciences, Taiyuan University of Science and Technology, Huazhong University of Science and Technology, Taiyuan University of Technology

发表论文 21 篇 · 总被引 275 次 · h-index 7

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 187)
• Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS). (2022 · Journal of Clinical Oncology · 被引 15)
• A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC). (2022 · Journal of Clinical Oncology · 被引 15)
• Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies (2025 · Signal Transduction and Targeted Therapy · 被引 14)
• Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors. (2022 · Journal of Clinical Oncology · 被引 10)
• GLMKD: Joint global and local mutual knowledge distillation for weakly supervised lesion segmentation in histopathology images (2025 · Expert Systems with Applications · 被引 9)